Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.

Date publication

février 2016

Journal

Rheumatology (Oxford, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric

Tous les auteurs :
Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, Kahn JE, Hamidou M, Park S, Puéchal X, Toussirot E, Falgarone G, Launay D, Morel N, Trouiller S, Mathian A, Gombert B, Schoindre Y, Lioger B, De Wazieres B, Amoura Z, Buchdaul AL, Georgin-Lavialle S, Dion J, Madaule S, Raffray L, Cathebras P, Piette JC, Rose C, Ziza JM, Lortholary O, Montestruc F, Omouri M, Denis G, Rossignol J, Nimubona S, Adès L, Gardin C, Fenaux P, Fain O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26350487

Résumé

We describe myelodysplastic syndrome (MDS)-associated systemic inflammatory and autoimmune diseases (SIADs), their treatments and outcomes and the impact of SIADs on overall survival in a French multicentre retrospective study.

Mots clés

autoimmune disorders, myelodysplastic syndrome, outcome, treatment

Référence

Rheumatology (Oxford). 2016 Feb;55(2):291-300